Navigation Links
SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology
Date:9/19/2011

SuviCa Inc. of Boulder and the University of Colorado recently completed an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer.

The patented drug discovery tool, developed by CU-Boulder Associate Professor Tin Tin Su of the molecular, cellular and developmental biology department, uses a genetically modified Drosophila fruit fly model to screen for compounds effective against various types of cancer, either alone or in combination with existing therapies.

The screening technique will be used to identify new clinical candidates using a methodology that is both time efficient and cost-effective. Because it uses a whole-animal screening model, the technique can more easily eliminate drug candidates with undesired toxicity.

"SuviCa looks forward to advancing Dr. Su's technology in order to find better ways to treat cancer patients and to build a world-class business in the Front Range region," said Judy Hemberger, SuviCa's chairman and CEO.

"We are excited about the commercial possibilities for the drug screening technology developed by Dr. Su, which has already been used at CU to identify promising therapeutic candidates," said Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office, or TTO.

SuviCa recently received funding from Colorado's Bioscience Discovery Evaluation Grant Program, an initiative launched in 2007 by the state of Colorado's Office of Economic Development and International Trade to provide early-stage, matching seed grants to enable the development and commercial validation of promising technologies that are licensed from Colorado research institutions.

SuviCa also has received a grant from the Internal Revenue Service through the Qualifying Therapeutic Discovery Project Program aimed at small businesses. Current and future efforts will focus on identifying and optimizing additional lead compound
'/>"/>

Contact: Lindsay Lennox
lindsay.lennox@cu.edu
303-735-5518
University of Colorado at Boulder
Source:Eurekalert

Page: 1 2

Related biology news :

1. CU-Boulder study suggests air quality regulations miss key pollutants
2. New CU-Boulder study shows diversity decreases chances of parasitic disease
3. Evolution education for K-12 teachers needs beefing up, says CU-Boulder professor
4. CU-Boulder study shows 53 million-year-old high Arctic mammals wintered in darkness
5. CU-Boulder study shows Maya intensively cultivated manioc 1,400 years ago
6. Noise pollution negatively affects woodland bird communities, says CU-Boulder study
7. Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study
8. CU-Boulder team identifies DNA "barcodes to help track illegal trading of wildlife products
9. 3 payloads built by CU-Boulder set for launch on space shuttle Atlantis
10. Swan song of space shuttle Discovery to carry 2 payloads built by CU-Boulder
11. Final flight of space shuttle Discovery to carry 2 payloads built by CU-Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... -- (July 29, 2009) -- Italian and U.S. biologists this ... rare genetic disorder plays an unexpected and critical role in ... in the journal Nature shows that the protein, ... a previously undocumented way. "If you,d asked me a ...
... obesity have tripled in the last 25 years, putting many ... a report in Academic Pediatrics by an obesity ... Baptist Medical Center. "Children are not only becoming ... said Joseph Skelton, M.D., lead author and director of the ...
... is a longtime user of the Advanced Light Source ... to major advances in lensless imaging. It,s a particularly ... they can,t be focused with ordinary lenses. ... in faster pulses, lensless imaging becomes ever more critical ...
Cached Biology News:Little-known protein found to be key player 2Research shows rates of severe childhood obesity have tripled 2Jet-propelled imaging for an ultrafast light source 2Jet-propelled imaging for an ultrafast light source 3Jet-propelled imaging for an ultrafast light source 4Jet-propelled imaging for an ultrafast light source 5Jet-propelled imaging for an ultrafast light source 6
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... August 15 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... in the acquisition, development and,commercialization of therapeutics for ... and hepatitis C, today announced its,financial results for ... At June 30, 2007, the Company had cash, ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), ... period under,Hart-Scott-Rodino Antitrust Improvements Act of 1976 with ... BETA 3) from Renovo Group plc,(LSE: RNVO) expired ... terms, the,License Agreement became effective on August 15, ...
... Amyris Co-founder Recognized for Role in Engineering Microbes to Produce ... TR35 2007 Recipients to be Honored at Technology Review,s ... ... Amyris Biotechnologies is,pleased to announce that Neil Renninger, Ph.D., ...
Cached Biology Technology:XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3
... Application: For the efficient enrichment of ... tissue or cell culture. The isolated ... degradation and metabolic pathway analysis. Metabolic ... deficiency in children, cystic fibrosis and ...
Plasmid expressing the LacZ reporter gene....
... PYREX Fernbach-style culture flasks have triple baffles ... bottom to achieve maximal oxygen transfer to ... marking spot., A wide range of optional ... Polypropylene colored caps for ease of ...
...
Biology Products: